secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001628908-25-000098
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent reaffirms FY2025 Adj. EBITDA guidance $135-165M; secures Ares non-dilutive financing
--------------------------------------------------------------------------------

- Reaffirmed FY2025 Adj. EBITDA guidance $135-165M and Q2 2025 guidance $33-40M.
- Oncology cost trend below expectations through May; if continues, expects Q2 Adj. EBITDA in top half of range.
- Secured Commitment Letter with Ares for Incremental Facility to retire 2025 Convertible Notes; non-dilutive debt option.
- Amendment No. 5 to Credit Agreement modifies liquidity test, adds default if Exchange not consummated.
- Accelerating organic new revenue bookings forecast for 2026 go-lives due to high market demand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890825000098/0001628908-25-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890825000098/evh-20250619.htm
  HTML page:      https://secwatch.observer/filing/0001628908-25-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer